Blepharitis
Conditions
Interventions
Eligible 96 patients, that fulfill the inclusion criteria for dry eye syndrome and blepharitis due to Meibomian gland disfunction. Patients will be divided in two groups: 48 patients treated with iLU
Sponsors
Clínica Oftalmológica Pereira Gomes
Clínica Oftalmológica de Antioquia
Fundación Oftalmológica Los Andes
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years; Patients who signed the consent form; Availability to attend all study visits; Positive history of dry eye symptoms prior to the study, using ocular surface disease index greater than or equal to 13 at patient's first visit; Evidence of Meibomian gland disfunction, diagnosed by a clinician not involved in the study and defined as a Meibomian gland secretion score less than 12 in 15 glands assessed in the lower eyelid; Non-invasive tear film break-up time (NIBUT) less than 10 seconds using the Keratograph 5M; Consent/ability to abstain from other dry eye/Meibomiun gland disfunction medications during the time between the screening visit and the end of the study;
Exclusion criteria
Exclusion criteria: Ocular surgery in the last 6 months; Cicatricial lid margin disease (symblepharon) identified by slit-lamp examination; Active ocular infection or active ocular inflammation or history of chronic, recurrent ocular inflammation within the prior 3 months; Treatment with LIpiFlow or Intense Pulsed Light Therapy in the previous 12 months; Treatment with omega-3; Use of topical cyclosporine; Use of topical steroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effectiveness of iLUX treatment in patients with Meibomian gland dysfunction. We expect that the meibomian gland secretion scores increases from baseline measurements (4.0 more or less 3.4) to one month post-treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Increasing baseline tear break-up time (continuous measures) over the four assessments across the time of thirty days, evaluated by both invasive and non-invasive tear film break-up time. And improvement in ocular surface disease index symptom score (continuous measure) over four subsequent measures within one month. | — |
Countries
Brazil, Chile, Colombia
Contacts
Public ContactJosé Alvaro;Felipe Gomes;Santana
Universidade Federal de São Paulo ;Fundación Oftalmológica Los Andes
Outcome results
None listed